CST, 2112S, Cycloheximide

Chemical Modulators for studying in the research area. Product Usage Information Cycloheximide is supplied as a lyophilized powder. For a 10 mg/ml stock, carefully weigh out and reconstitute 50 mg in 5 ml DMSO or EtOH. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 5-50 µg/ml for 4-24 hours. Soluble in DMSO, EtOH, or MeOH. Wear personal protective equipment. Do not empty product into drains. Do not handle until all safety precautions have been read and understood. Safety Information: Cycloheximide is suspected of causing genetic defects. It may cause adverse reproductive effects - such as birth defect, miscarriages, or infertility. Avoid contact during pregnancy and while nursing. If exposed or concerned, get medical advice. See Safety Data Sheet (SDS). Storage Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. Background Cycloheximide is a protein synthesis inhibitor in eukaryotes. Although its precise mechanism of action has yet to be fully elucidated, it has been shown to inhibit translation elongation through binding to the E-site of the 60S ribosomal unit and interfering with deacetylated tRNA (1-3). Although not all cell types are equally sensitive to the apoptosis-inducing effects of cycloheximide, it has been shown to induce cell death in T cells through a FADD-dependent mechanism (4). In addition, cycloheximide and Tumor Necrosis Factor possess a synergistic cytotoxicity (5,6), and consequently they are routinely used together to induce cell death. Investigators have demonstrated that cycloheximide blocks bortezomib-stimulated protein ubiquitination (7). Alternate Names apoptosis; bortezomib; CHX; cleaved parp; protein synthesis inhibitor; TNF; Tumor Necrosis Factor; ubiquitin